Regulatory effect of trotagliptin on fasting blood glucose in patients with diabetes

Trelagliptin (Trelagliptin), an advanced dipeptidyl peptidase-4 (DPP-4) inhibitor, has been proven to have a positive impact on fasting blood glucose management in patients with diabetes. DPP-4 enzyme plays an important role in degrading the gastrointestinal hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) in the body. GLP-1 and GIP can effectively stimulate the release of insulin and inhibit the secretion of glucagon, thereby achieving the effect of lowering blood sugar.

Compared with some other oral antidiabetic drugs, the hypoglycemic effect of trotagliptin is milder, but this does not affect its excellent safety performance and neutral effect on body weight. It is worth mentioning that trotagliptin promotes insulin secretion in a glucose-dependent manner, so it does not alone cause hypoglycemia. This is crucial for people with diabetes, as low blood sugar can cause serious health problems such as confusion.

Scientific research shows that troagliptin has a significant effect in regulating fasting blood sugar. A clinical trial focusing on patients with type 2 diabetes revealed that patients treated with troagliptin had a significant reduction in fasting blood glucose levels within 12 weeks. At the same time, trotagliptin can also help reduce glycated hemoglobin (HbA1c) levels, which is an important parameter for measuring long-term blood sugar control.

However, individual responses to medications vary widely. Therefore, before starting tretagliptin or any other antidiabetic drug, patients should first consult their doctor and follow their doctor's instructions carefully. The doctor will tailor the most suitable treatment plan for the patient based on the patient's type of diabetes, disease progression and other related factors.